Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study
- PMID: 22162140
- PMCID: PMC3725780
- DOI: 10.1002/jbmr.1489
Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study
Abstract
Several prior investigations demonstrate an improvement in bone mineral density associated with use of tumor necrosis factor inhibitors (TNFi). We compared the risk of osteoporotic fractures among patients with rheumatoid arthritis (RA) initiating a disease-modifying antirheumatic drug (DMARD). A population-based cohort study was conducted using health care utilization data (1996-2008) from a Canadian province and a U.S. commercial insurance plan. Patients with at least two RA diagnoses were identified, and follow-up began with the first prescription for a DMARD. Drug regimens were categorized into three mutually exclusive hierarchical groups: (1) TNFi with or without nonbiologic DMARDs (nbDMARD), (2) methotrexate (MTX) without a TNFi, or (3) other nbDMARD without a TNFi or MTX. Main outcomes were hospitalizations for fractures of the hip, wrist, humerus, or pelvis based on diagnoses and procedure codes. The study cohort consisted of 16,412 RA patients with 25,988 new treatment episodes: 5856 TNFi, 12,554 MTX, and 7578 other nbDMARD. The incidence rate per 1000 person-years for osteoporotic fracture were 5.11 [95% confidence interval (CI) 3.50-7.45] for TNFi, 5.35 (95% CI 4.08-7.02) for MTX, and 6.38 (95% CI 3.78-10.77) for other nbDMARD. After multivariable adjustment for osteoporosis and fracture-related risk factors, the risk of nonvertebral osteoporotic fracture was not different in either TNFi [hazard ratio (HR) 1.07, 95% CI 0.57-1.98] or MTX (HR 1.18, 95% CI 0.60-2.34) compared with nbDMARD. Among subjects diagnosed with RA, the adjusted risk of nonvertebral fracture was similar across persons starting a TNFi, MTX, or other nbDMARD.
Copyright © 2012 American Society for Bone and Mineral Research.
Figures
Similar articles
-
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.JAMA. 2011 Jun 22;305(24):2525-31. doi: 10.1001/jama.2011.878. JAMA. 2011. PMID: 21693740
-
Medications associated with fracture risk in patients with rheumatoid arthritis.Ann Rheum Dis. 2019 Aug;78(8):1041-1047. doi: 10.1136/annrheumdis-2019-215328. Epub 2019 May 15. Ann Rheum Dis. 2019. PMID: 31092411
-
Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.Osteoporos Int. 2020 Nov;31(11):2131-2139. doi: 10.1007/s00198-020-05488-9. Epub 2020 Jun 8. Osteoporos Int. 2020. PMID: 32514765
-
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7. Pharmacoeconomics. 2018. PMID: 29882210 Review.
-
Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2018 Jul;36(7):769-778. doi: 10.1007/s40273-018-0616-7. Pharmacoeconomics. 2018. PMID: 29502174 Free PMC article. Review.
Cited by
-
Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study.Nagoya J Med Sci. 2019 Nov;81(4):571-585. doi: 10.18999/nagjms.81.4.571. Nagoya J Med Sci. 2019. PMID: 31849375 Free PMC article.
-
Impact of Rheumatoid Arthritis and Its Management on Falls, Fracture and Bone Mineral Density in UK Biobank.Front Endocrinol (Lausanne). 2019 Nov 26;10:817. doi: 10.3389/fendo.2019.00817. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31849841 Free PMC article.
-
Glucocorticoids: bad or safe for the bones?RMD Open. 2015 Aug 15;1(Suppl 1):e000050. doi: 10.1136/rmdopen-2015-000050. eCollection 2015. RMD Open. 2015. PMID: 26557373 Free PMC article.
-
Tart Cherry Prevents Bone Loss through Inhibition of RANKL in TNF-Overexpressing Mice.Nutrients. 2018 Dec 29;11(1):63. doi: 10.3390/nu11010063. Nutrients. 2018. PMID: 30597968 Free PMC article.
-
Mechanisms of Systemic Osteoporosis in Rheumatoid Arthritis.Int J Mol Sci. 2022 Aug 5;23(15):8740. doi: 10.3390/ijms23158740. Int J Mol Sci. 2022. PMID: 35955873 Free PMC article. Review.
References
-
- Lane N, Pressman A, Star V, et al. Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1995;10(2):257–263. - PubMed
-
- van Staa T, Geusens P, Bijlsma J, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104–3112. - PubMed
-
- Coulson K, Reed G, Gilliam B, et al. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009;15(4):155–160. - PubMed
-
- de Jong Z, Munneke M, Lems W, et al. Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial. Arthritis Rheum. 2004;50(4):1066–1076. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical